Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

18 years < age < 80 years
ASA socre is Ⅰ-Ⅲ
Pathological rectosigmoid carcinoma
...
18 years < age < 80 years
ASA socre is Ⅰ-Ⅲ
Pathological rectosigmoid carcinoma
Tumor located in rectosigmoid (defined as 10- to 30-cm from the anal verge)
Informed consent
Preoperative T stage ranging from T1 to T4a according to the 7th Edition of AJCC Cancer Staging Manual
Tumor size of 5 cm or less; 6) ECOG score is 0-1

Exclusion Criteria

Body mass index (BMI) >30 kg/m2
Pregnant woman or lactating woman
Severe mental disease
...
Body mass index (BMI) >30 kg/m2
Pregnant woman or lactating woman
Severe mental disease
Requirement of simultaneous surgery for other disease
Previous abdominal surgery
Emergency operation due to complication (bleeding, perforation or obstruction) caused by colorectal cancer

Summary

Conditions
Colorectal Cancer
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 80 years
Gender
Both males and females

Inclusion Criteria

18 years < age < 80 years
ASA socre is Ⅰ-Ⅲ
Pathological rectosigmoid carcinoma
...
18 years < age < 80 years
ASA socre is Ⅰ-Ⅲ
Pathological rectosigmoid carcinoma
Tumor located in rectosigmoid (defined as 10- to 30-cm from the anal verge)
Informed consent
Preoperative T stage ranging from T1 to T4a according to the 7th Edition of AJCC Cancer Staging Manual
Tumor size of 5 cm or less; 6) ECOG score is 0-1

Exclusion Criteria

Body mass index (BMI) >30 kg/m2
Pregnant woman or lactating woman
Severe mental disease
...
Body mass index (BMI) >30 kg/m2
Pregnant woman or lactating woman
Severe mental disease
Requirement of simultaneous surgery for other disease
Previous abdominal surgery
Emergency operation due to complication (bleeding, perforation or obstruction) caused by colorectal cancer

Tracking Information

NCT #
NCT02117557
Collaborators
Not Provided
Investigators
  • Principal Investigator: Guoxin Li, M.D., PH.D. Nanfang Hospital, Southern Medical University, China
  • Guoxin Li, M.D., PH.D. Nanfang Hospital, Southern Medical University, China